EMA Authorised: Accofil (filgrastim) — Accord Healthcare S.L.U.

View source ↗

Summary

The European Medicines Agency authorised Accofil, a filgrastim biosimilar from Accord Healthcare S.L.U., for EU marketing to prevent chemotherapy-induced neutro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia
• Hematopoietic Stem Cell Mobilization

Drugs mentioned

• Accofil (filgrastim)

Snippet

Status: Authorised. MAH: Accord Healthcare S.L.U.. Decision date: 12/06/2025